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Autophagy is an evolutionarily conserved intracellular degra-
dation/recycling system that is essential for cellular homeostasis
but is dysregulated in a number of diseases, including myocar-
dial hypertrophy. Although it is clear that limiting or accelerat-
ing autophagic flux can result in pathological cardiac remodel-
ing, the physiological signaling pathways that fine-tune cardiac
autophagy are poorly understood. Herein, we demonstrated
that stimulation of cardiomyocytes with phenylephrine (PE), a
well known hypertrophic agonist, suppresses autophagy and
that activation of focal adhesion kinase (FAK) is necessary for
PE-stimulated autophagy suppression and subsequent initia-
tion of hypertrophic growth. Mechanistically, we showed that
FAK phosphorylates Beclin1, a core autophagy protein, on Tyr-
233 and that this post-translational modification limits Beclin1
association with Atg14L and reduces Beclin1-dependent
autophagosome formation. Remarkably, although ectopic
expression of wild-type Beclin1 promoted cardiomyocyte atro-
phy, expression of a Y233E phosphomimetic variant of Beclin1
failed to affect cardiomyocyte size. Moreover, genetic depletion
of Beclin1 attenuated PE-mediated/FAK-dependent initiation
of myocyte hypertrophy in vivo. Collectively, these findings
identify FAK as a novel negative regulator of Beclin1-mediated
autophagy and indicate that this pathway can facilitate the pro-
motion of compensatory hypertrophic growth. This novel
mechanism to limit Beclin1 activity has important implications
for treating a variety of pathologies associated with altered
autophagic flux.
Macroautophagy is an evolutionarily conserved intracellular
degradation/recycling process in which cytoplasmic cargo is
non-selectively enveloped within double-membraned vesicles
called autophagosomes that are transported to and fuse with
lysosomes. Within these so-called autolysosomes, cytoplasmic
cargo and the inner membrane are degraded so that the amino
acids, fatty acids, and glucose released can be used to support
cellular metabolism or to synthesize new proteins. Cardiomyo-
cytes are both highly metabolically active cells and long-lived
cells and as such are particularly dependent on macroau-
tophagy (hereafter referred to as autophagy) for energy produc-
tion and removal of damaged organelles or misfolded proteins.
However, in some cases up-regulation of autophagy (or failure
of autophagy suppression) can lead to detrimental cardiac
remodeling.
Autophagy is regulated in a stepwise fashion that involves
the formation of distinct protein complexes composed of
autophagy-related genes (Atg proteins) and their enzymatic
binding partners. Nutrient deprivation-induced activation of
the AMP kinase/Unc-51-like autophagy-activating kinase 1
(ULK) kinase cascade leads to the recruitment of core proteins
VPS34, VPS15, and Beclin1 (complex I) to endoplasmic reticu-
lum exit sites to form phosphatidylinositol 1,4,5-phosphate 3-
kinase-dependent double membrane autophagosome precur-
sors. Complex I then facilitates the recruitment of additional
proteins, including the phosphatidylinositol 3-phosphate-
binding WIPI/ATG18-ATG2 complex and the ubiquitin-like
ATG8/LC3-phospatidylethanol conjugation system, to drive
membrane expansion and the formation of a phagophore and
eventually to promote phagophore closure to form an autopha-
gosome. The final step of autophagosome-lysosome fusion is
mediated by a second Beclin1-containing complex (complex II)
in which UVRAG bridges Beclin1 with Vps34/Vps15 on the
surface of the lysosome (1).
Numerous studies indicate that tight spatial and temporal
regulation of autophagy is necessary for both basal cardiac
function and for protection from pathological remodeling fol-
lowing ischemic or hemodynamic stress (2, 3). The finding that
cardiac-restricted depletion of the autophagy related gene 5
(Atg5; a protein essential for the capture of ubiquitinated pro-
teins and LC3-dependent expansion of autophagosomes) led to
progressive contractile dysfunction in adultmice in the absence
of a pathological insult indicates that a basal level of autophagy
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is necessary for cardiac function (4). Autophagy is elevated fol-
lowing ischemia/reperfusion (I/R)3 injury, and numerous stud-
ies have revealed that autophagy plays an important cardio-
protective role in this setting. For example, treatment with
bafilomycin A (which blocks lysosomal degradation of
autophagosomes) or expression of a dominant-inhibitory vari-
ant of Atg5 worsened I/R-mediated injury and promoted the
accumulation of damaged mitochondria in this setting (5, 6).
However, the finding that Beclin1/ mice (that exhibit
decreased autophagy) were protected from I/R damage indi-
cates that in some cases suppression of autophagy (or at least
limiting Beclin1-dependent induction of autophagy) can be
beneficial (7, 8). Interestingly, genetic deficiency in Beclin1
impaired the regression of cardiac hypertrophy induced by
mechanical or neurohumoral unloading (9, 10) indicating that
Beclin1-dependent autophagy might also play an important
role in myocyte atrophy. Notably, although cardiac autophagy
is increased following I/R, autophagy is suppressed during com-
pensatory hypertrophic growth in response tomoderate hemo-
dynamic stress (4) or stimulation with the -adrenergic agonist
isoproterenol (11). However, the molecular mechanisms
underlying autophagy suppression and its consequences
with respect to adrenergic signaling-dependent hypertrophic
growth remain unclear.
As noted above, Beclin1 plays a critical role in both autopha-
gosome formation and autophagosome-lysosome fusion, and
recent studies reveal that Beclin1 serves as a nexus for
autophagy regulation in response to various signaling path-
ways. For example, Beclin1 ubiquitination is promoted by
tumor necrosis factor receptor-associated factor 6 (TRAF6)
(12), neural precursor cell-expressed developmentally down-
regulated 4 (Nedd4) (13), andAmbra1 (14). Beclin1 is also phos-
phorylated by serine/threonine kinases Akt (15), Mst1 (16),
Ulk1 (17), ROCK1 (18), and MAPKAPK2/3 (19) as well as the
receptor tyrosine kinase epidermal growth factor receptor
(EGFR) (20). Each of these post-translational modifications
alters the ability of Beclin1 to associate with complex I and II
proteins or with the autophagy inhibitors Bcl2 and Rubicon.
However, despite findings that limitingBeclin1 activity ismark-
edly cardioprotective and may govern compensatory cardiac
growth, we know very little about the molecular mechanisms
that regulate Beclin1 function in the heart.
We and others have reported that 1-adrenergic stimulation
of cardiac hypertrophy was augmented by integrin-dependent
activation of focal adhesion kinase (FAK) (21, 22), and mice
deficient in FAK were resistant to pressure overload-induced
hypertrophy (23, 24). Because FAK is a critical downstream
regulator of cardiac integrins and growth factor receptors that
are known to inhibit autophagy (25), we explored the possibility
that FAKmight promote the initiation of hypertrophic growth,
at least in part by suppressing autophagy-induced myocyte
atrophy. Indeed, we found that FAK is both sufficient and nec-
essary for -adrenergic signaling-dependent autophagic sup-
pression in vitro and in vivo. Collectively, our studies described
herein identify FAK as a novel negative regulator of Beclin1-
mediated autophagy and indicate that repression of Beclin1-de-
pendent autophagy can facilitate the initiation of hypertrophic
cardiac growth.
Results
Activation of FAK Suppresses Starvation-induced Car-
diomyocyte Autophagy—We previously showed that elevated
FAK activity limits cardiomyocyte apoptosis and provides
remarkable cardioprotection in the face of various pathological
stressors (26, 27). Because recent evidence indicates that apo-
ptotic and autophagic signaling pathways are intimately inter-
linked and because activation of integrins (the major upstream
regulators of FAK) is known to limit autophagy (25), we rea-
soned that levels of cardiac FAK activitymight also impart con-
trol over autophagic flux. To explore a putative role for FAK in
cardiomyocyte autophagy, we evaluated levels of canonical
autophagic markers in nutrient-deprived primary neonatal rat
cardiomyocytes (NRCMs) infected with adenoviruses express-
ing green fluorescent protein (GFP, control) or an active FAK
variant (K578E/K581E) termed SuperFAK that exhibited
enhanced catalytic activity (28). As shown in Fig. 1A, SuperFAK
expression induced a robust increase in protein levels of p62
(also known as Sequestosome 1, or SQSTM1, a substrate
degraded by autophagy) and a decrease in the conversion of the
cytosolic precursor form of microtubule-associated protein
light chain 3 (LC3-I) to the autophagosome-localized, cleaved,
and lipidated form (LC3-II) as assessed by both quantification
of LC3-II/LC3-I ratios and total LC3-II levels. Autophagic vac-
uoles can be visualized and quantified by ectopic expression of
epitope-taggedLC3, and as shown in Fig. 1B, ectopic expression
of SuperFAK in HL-1 atrial cardiomyocytes (29) significantly
reduced the number of RFP-LC3puncta, providing further sup-
port that FAK activity suppresses autophagy. Suppression of
autophagic flux was confirmed in a separate set of experiments
using the lysosome inhibitor, chloroquine (CQ) to block
autophagy at the substrate degradation step. As expected, incu-
bation with CQ led to a robust increase in LC3-II levels in all
samples, but ectopic expression of SuperFAK significantly
reduced LC3 turnover (i.e. the difference of LC3-II levels in the
presence and absence of CQ as quantified using previously
reported methods (Fig. 1C) (30). Notably, SuperFAK-depen-
dent autophagic suppression was abolished by treatment with
PF-573228 (PF-228), an inhibitor of FAK catalytic activity (Fig.
1D). Collectively, these studies indicate that elevating FAK
activity might provide an effective means to dampen auto-
phagic flux.
-Adrenergic Signaling Limits Cardiac Autophagy via FAK
Activation—We have shown that phenylephrine (PE)-depen-
dent activation of myocardial 1-adrenergic receptor induces
FAK activity, and others have shown that compensatory hyper-
trophic signaling induced by relatedGq-coupledGPCRs is asso-
ciated with a blunted autophagic response (4, 11, 31). Although
a recent report indicated that long term treatment with PE led
to adrenergic stress-induced autophagy (32), we reasoned that
PE might limit autophagy during the initial compensatory
3 The abbreviations used are: I/R, ischemia/reperfusion; FAK, focal adhesion
kinase; PE, phenylephrine; NRCM, neonatal rat cardiomyocyte; GPCR,
G-protein-coupled receptor; EGFR, epidermal growth factor receptor; CQ,
chloroquine; PF-228, PF-573228; TAC, transverse aortic constriction; EGFP,
enhanced GFP; ECD, evolutionarily conserved domain; MFKO, myocyte-
restricted FAK knock-out; SF, SuperFAK.
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phasewhen FAK is active. To test this postulate, we first treated
C57Bl/6 mice with a single injection of PE at a concentration
previously shown to induce compensatory hypertrophy (20
mg/kg, s.c.) (33) and evaluated myocardial p62 and LC3-I and
-II levels 24 h following treatment. At this time point PE
induced a marked increase in p62 protein levels and a concom-
itant decrease in the LC3-II/LC3-I ratio and total LC3-II levels
but did not alter heart weight (Fig. 2A, data not shown), indi-
cating that PE treatment suppresses autophagy prior to the pro-
motion of hypertrophy. Although Beclin1 levels have been
shown to positively correlate with autophagy in severe pressure
overload-induced cardiac hypertrophy (34), no change in
Beclin1 protein levels was observed following 24 h of PE treat-
ment (Fig. 2A). Importantly, treatment of serum-starved
NRCM with PE (50 M) induced a time-dependent increase in
p62 protein and a decrease in the LC3-II/LC3-I ratio and total
FIGURE 1. Activation of FAK limits cardiomyocyte autophagy. A, NRCMs were infected with GFP or SuperFAK adenoviruses for 72 h, and cell lysates were
blotted with indicated antibodies with GAPDH as a loading control. Quantification shown on right, n  3; *, p  0.05; **, p  0.01 versus GFP. B, HL-1
cardiomyocytes were co-transfectedwith RFP-LC3 or HA-Beclin1 for 30 h, followed by infectionwith GFP or SuperFAK adenoviruses for 18 h and starvation for
4 h in the presence of CQ. Cells were then fixed with 4% paraformaldehyde and stained to detect HA (purple) and nuclei (DAPI, blue). GFP- (asterisk) or
SuperFAK-infected cells appear green. Overexpression of SuperFAK reduced the number of RFP-LC3 puncta (autophagosomes, arrow). ***, p 0.001 versus
GFP.Quantification representsmean S.E. of three independent experiments (at least 50 cells positive for RFP-LC3,GFP, andHA-Beclin1were analyzed in each
group). Scale bar, 10 m. C, NRCMs were infected with GFP or SuperFAK adenoviruses for 48 h. The lysosomal inhibitor CQ (10 M) was added to half of the
samples to assess autophagic flux. LC3-II turnover is defined as the amount of LC3-II delivered to lysosomes for degradationwithin a certain period of time and
calculated by subtracting LC3-II band intensity in the presence of CQ with that in the absence of CQ. *, p 0.05 versus GFP. D, NRCMs were infected with GFP
or SuperFAKadenoviruses for 48hwithorwithout thepotent and selective FAK inhibitor PF-228 in the last 24h. *,p0.05; **,p0.01.NS, not significant. Data
are mean S.E. of three independent experiments. All data were analyzed using two-tailed Student’s t tests.
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FIGURE 2. Activation of -adrenergic signaling suppresses cardiac autophagy. A, C57BL/6 mice received a single injection of PE (20 mg/kg, s.c.) or saline
control (n 4 in each group). Hearts were harvested. and protein lysates were blotted using indicated antibodies with GAPDH as a loading control. B,NRCMs
were treated with PE (50 M) for various times from 2 to 24 h. Cell lysates were blotted with indicated antibodies. Quantification of p62 and LC3-II/LC3-I ratio
and LC3-II levels are shown on right in A and B. *, p 0.05; **, p 0.01 versus non-treated control. Results are mean S.E. of three independent experiments.
C,NRCMs were incubated with PE (50M) for 24 h with or without CQ (10M) in the last 4 h of treatment. LC3-II turnover was calculated by subtracting LC3-II
band intensity in the presence of CQ with that in the absence of CQ. *, p 0.05 versus vehicle. D, NRCMs were treated with PE (50 M) or vehicle for 4 h in the
presence of CQ (10M). Cells were subsequently stainedwith the CYTO-ID autophagy detection kit was used to visualize autophagic vacuoles (green puncta).
Treatmentwith PE significantly reduced puncta formation. *, p 0.05 versus vehicle. At least 50 cells were examined per sample. Data aremean S.E. of three
independent experiments. Scale bar, 20m. **, p 0.01. E, CAG-RFP-EGFP-LC3mice were transferred to food-free cages and received a single injection of PE
(20mg/kg, s.c.) or saline control (n 3 in each group), and hearts were collected at 24 h. The lysosomal acidification inhibitor bafilomycin A1 was injected 2 h
before euthanization. Autophagosomes appear orange, and autolysosomes appear red. Number of puncta was quantified from at least five different high
power fields. *, p 0.05. NS, not significant. Data were analyzed using two-tailed Student’s t tests.
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LC3-II levels (Fig. 2B), indicating that PE-mediated autophagic
suppression is autonomous to cardiomyocytes. Moreover, LC3
turnover was reduced in cells treated with PE and CQ, indicat-
ing that PE treatment inhibited autophagic flux in cardiacmyo-
cytes (Fig. 2C). Accordingly, PE treatment significantly attenu-
ated serum starvation-induced accumulation of autophagic
puncta in NRCMs (Fig. 2D) and in intact hearts as assessed
using fasted transgenic RFP-GFP-LC3 mice treated with bafi-
lomycin A1 (Fig. 2E) (35). Together, these results indicate that
adrenergic signaling and elevated signaling through FAK lead
to a similar transient suppression of cardiac autophagy.
We next sought to determine whether PE-inhibited auto-
phagy in a FAK-dependent fashion. Importantly, treatment of
NRCM with PE induced a robust increase in FAK activity as
assessed by increased auto-phosphorylation at Tyr-397 and
increased Src-dependent phosphorylation of FAK at Tyr-576/
577 and Tyr-925, collective indicators of full FAK catalytic acti-
vation (Fig. 3A). Importantly, siRNA-mediated knockdown of
FAK fully attenuated PE-induced changes in p62 levels and LC3
modification, whereas knockdown of FAK only modestly
increased basal autophagy (Fig. 3B) and autophagic flux (data
not shown). Pre-treatment with the selective FAK inhibitor,
PF-228, also abolished the PE-induced increase in p62 and
blunted PE-induced changes in LC3-II (Fig. 3C). Moreover, PE
failed to reduce the number of autophagic puncta induced by
serum starvation when cultured primary cardiomyocytes were
pre-treated with PF-228 (Fig. 3D). We next used our cardiac-
restricted FAK gain- or loss-of-function mouse models to
assess the extent that FAK contributes to PE-mediated
autophagy suppression in vivo. Although fed/unstimulated car-
diac-specific SuperFAK transgenic (SF2) mice tended to have
lower levels of LC3-II than WT littermates, this effect was not
significantly different. Similarly, basal autophagy was not
altered in hearts frommyocyte-restricted FAK knock-out mice
when compared with WT hearts (Fig. 3E). This lack of effect
could be due to compensation over time as thesemodels exhibit
early post-natal changes in cardiac FAK activity (23). However,
the ability of PE to suppress basal autophagy was significantly
blunted in the hearts from MFKO mice and significantly aug-
mented in the hearts from SF2 mice relative to littermate con-
trols (Fig. 3, F–H). These data indicate that PE signals through
FAK to limit cardiac autophagy. We next determined whether
elevated FAK activity can limit cardiac autophagy following
mechanical overload by subjecting SF2 mice and littermates to
either moderate or severe aortic constriction (induced by ligat-
ing the aorta to the width of a 27- or 28-gauge needle, respec-
tively) for 3 days (34). SuperFAK was capable of suppressing
cardiac autophagy-induced moderate hemodynamic overload
(Fig. 3I). However, although SuperFAKwas also clearly capable
of limiting autophagy following severe pressure overload as
assessed by elevated p62 levels and reduced LC3II/LC3I ratio,
total LC3II levels were increased in these mice (Fig. 3J).
Although future studies will be important to fully understand
this finding, it is formally possible that accumulation of LC3II in
this model results from a combination of a compensatory
induction of autophagy by endoplasmic reticulum or mito-
chondrial stress pathways combined with a reduction in auto-
phagy-dependent LC3II clearance. Collectively, these studies
indicate thatmodulation of FAKactivity can provide ameans to
control excessive autophagy in pathological settings.
FAK Phosphorylates the Core Autophagy Protein Beclin1 at
Tyr-233—Although FAK can associate with p85PI3K and pro-
mote p85PI3K/AKT signaling to limit autophagy in some can-
cer cell types (36), we previously reported that FAK does not
regulate AKT activity in cardiomyocytes (37), and our subse-
quent findings that phospho-AKT was not elevated in SF2
hearts either at baseline (data not shown) or following challenge
(Fig. 3J) indicates that FAK-dependent autophagy suppression
is likely not mediated by AKT signaling in these cells. Because
the catalytic activity of FAK was necessary to suppress
autophagy, we reasoned that FAK might phosphorylate a key
substrate of the core autophagy initiation complex. As noted
above, Beclin1 has been previously identified as a substrate for
both serine/threonine and tyrosine kinases (15, 20) and through
the use of the Group-based Prediction System algorithm (38),
we identified Tyr-233 (a site highly conserved from lower ver-
tebrates to mammals; Table 1) as a putative FAK phosphoryla-
tion site. To determine whether Beclin1 is a bona fide FAK
substrate, COS cells were co-transfected with HA-tagged
Beclin1 and FAK catalytic variants that included either wild-
type FAK, a kinase deficient non-phosphorylatable mutant
FAK (Y397F), or SuperFAK. Immunoprecipitation of HA-Be-
clin1 followed byWestern blotting with a pan-Tyr(P) antibody
revealed that Beclin1 tyrosine phosphorylation was markedly
induced by expression of SuperFAK and to a lesser extent by
wild-type FAK but not by the Y397F-FAK variant (Fig. 4A). To
test the hypothesis that FAK phosphorylates Beclin1 at Tyr-
233, a similar experiment was performed, and the blot was
probed with a specific phospho-Beclin1 (Tyr-233) antibody. As
shown in Fig. 4B, the level of phospho-Beclin1 (Tyr-233) was
dramatically increased by expression of SuperFAK but not by
FAK (Y397F). To test our postulate that Tyr-233 of Beclin1 is a
major FAK phosphorylation site, we tested the ability of Super-
FAK to induce phosphorylation of a Y233F Beclin1 variant. As
shown in Fig. 4C, mutation of Tyr-233 to Phe-233 completely
abolished SuperFAK-induced Beclin1 tyrosine phosphoryla-
tion, indicating that Tyr-233 is the sole FAK phosphorylation
site on Beclin1. Because FAK acts in a bipartite complex with
the tyrosine kinase pp60Src, we next explored whether FAK
kinase activity per se was necessary for Beclin1 Tyr-233 phos-
phorylation. Indeed, we found that treatment with the FAK-
specificcatalytic inhibitorPF-228attenuatedSuperFAK-depen-
dent Beclin1 phosphorylation without influencing total protein
expression (Fig. 4D) indicating that Beclin1 is a substrate for
FAK.Notably, in vitro kinase assays revealed that Beclin1 is also
a substrate for Src; however, active Src induced comparable
phosphorylation ofWT and Y233F-Beclin1, indicating that Src
and FAK likely phosphorylate distinct tyrosines (Fig. 4E).
Importantly, phosphorylation of endogenous Beclin1 on Tyr-
233 is evident in isolated cardiomyocytes following treatment
with PE underscoring the importance of this post-translational
modification in a physiological setting (Fig. 4F). Moreover, PE-
induced phosphorylation of Tyr-233 Beclin is induced in vivo
and is elevated in hearts from SuperFAK mice (Fig. 4G). The
subsequent finding that siRNA-mediated knockdown of
Beclin1 attenuated starvation-induced autophagic flux (data
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not shown) and SuperFAK-dependent increases in p62 protein
levels (Fig. 5A) highlights the importance of Beclin1 in mediat-
ing FAK-dependent autophagic suppression.
FAK-mediated Phosphorylation of Beclin1 at Tyr-233 Com-
promised Beclin1-dependent Autophagy—Because FAK sup-
pressed autophagy in a Beclin1dependent fashion, we reasoned
that phosphorylation of Tyr-233 might either enhance
Beclin1’s association with autophagy inhibitors (i.e. Bcl2 and
rubicon) or limit its associationwith complex I (Atg14L/Vps15/
Vps34) or complex II (UVRAG/Vps15/Vps34) binding partners
that are necessary for autophagosome formation or autophago-
some-lysosomal fusion, respectively (15, 16, 20, 39). As shown
in Fig. 5B, FAK inhibitionmarkedly enhanced the association of
HA-Beclin1 with Atg14L (i.e. complex I formation) but did not
influence UVRAG binding (i.e. complex II formation). FAK
inhibition induced a similar increase inAtg14L associationwith
endogenous Beclin1 in HL-1 cells (Fig. 5C). Conversely, co-
immunoprecipitation assays revealed that a phosphomimetic
Y233E Beclin1 variant exhibited a weaker interaction with
Atg14L and slightly stronger interaction with UVRAG when
comparedwithWTBeclin1 (Fig. 5B, right panels). BecauseTyr-
233 lies within the coiled-coil domain that is known to mediate
Atg14L association (40), it is likely that phosphorylation of this
site directly interferes with Atg14L binding. Although the
coiled-coil domain of Beclin1 is also responsible for Beclin1
homodimerization and inactivation, Tyr-233 phosphorylation
did not alter Beclin1 self-association as assessed by co-immu-
noprecipitation of FLAG- and HA-tagged WT or Y233E vari-
ants (data not shown). We next assessed a functional role for
Tyr-233 phosphorylation in Beclin1-dependent autophago-
some formation. To this end, we co-expressed GFP-LC3 with
HA-tagged Beclin1 variants in HL-1 cells and subjected the
cells to nutrient depletion for 4 h. As shown in Fig. 5D, WT
Beclin1 induced numerous GFP-LC3 puncta in starved HL-1
cells, whereas ectopic expression of the phosphomimetic vari-
ant Y233E induced significantly fewer puncta. Thus, FAK-de-
pendent phosphorylation of Beclin1 on Tyr-233 suppressed
autophagy by reducing Atg14L binding and limiting autopha-
gosome formation.
To further evaluate the regulation of Beclin1 by FAK,we next
investigated whether FAK and Beclin1 interact. Indeed, as
shown in Fig. 6A, WT Beclin1 co-immunoprecipitated with
WT FAKwhen co-expressed in COS cells. To map the interac-
tion site(s) of FAK on Beclin1, similar co-immunoprecipitation
experiments were performed in COS cells co-transfected with
Myc-FAK and various Beclin1 fragments. Amino acids 1–242
but not 1–150 of Beclin1 co-immunoprecipitated with FAK,
indicating that amino acids 151–242 (containing the CCD
domain) contribute to the interaction between Beclin1 and
FAK. In addition, the Beclin1 fragment 243–450 containing the
evolutionarily conserved domain (ECD) co-precipitated with
FAK. Thus, both the CCD and the ECD domain of Beclin1 are
capable of binding to FAK. The finding that FAK associates
more strongly with full-length Beclin1 than it does with either
individual domain suggests that these sites might act in a coop-
erative fashion to promote FAK binding. We next tested the
extent to which FAK activity might influence FAK-Beclin1
interactions. Interestingly, we found that inactive Y397F-FAK
interacted more strongly with Beclin1 than did WT FAK (Figs.
4A and 6B). Accordingly, short term treatment with the FAK
inhibitor (FAKi) significantly decreased FAK phosphorylation
at Tyr-397 and enhanced the interaction betweenWTFAK and
WTBeclin1 (Fig. 6C). AlthoughFAK inhibitionmay also lead to
de-phosphorylation of Beclin1 over time, the increased FAK-
Beclin1 association observed in the previous experiment was
not likely due to this occurrence because our subsequent stud-
ies revealed that phospho-deficient Y233F-Beclin1 actually
associated slightly less avidly with Y397F-FAK than did WT
Beclin1 (Fig. 6D). Collectively, these findings indicate that
nutrient starvation promotes Beclin1-Atg14L containing com-
plex formation and subsequent autophagosome formation. In
turn, FAK activation promotes Beclin1 Tyr-233 phosphoryla-
tion, reduces FAK-Beclin1 interactions, attenuates complex I
formation, and limits autophagy initiation (Fig. 6E). Thus, FAK
regulates Beclin1-dependent autophagy in an activation-state
specific manner.
FAK-dependent Suppression of Autophagy Promotes Car-
diomyocyte Hypertrophy—As we and others previously showed
that adrenergic signaling-induced cardiac hypertrophy was
mediated by activation of FAK (21, 22), we reasoned that FAK-
dependent autophagy suppression might underlie this growth
FIGURE 3. -Adrenergic-dependent autophagy suppression requires FAK. A, NRCMs were treated with PE (50 M) for various times from 2 to 24 h. Cell
lysates were blotted with indicated antibodies. Identical lysates were used in Fig. 2B. Results are representative of three independent experiments. Quantifi-
cation of FAK phosphorylation/total FAK is indicated (relative to the 0 time point) for three separate experiments. B, NRCMs were transfected with control or
FAK siRNA (25 nM) for 72 h prior to treatment with PE (50M) for 24 h. Cell lysates were blottedwith indicated antibodies (right panel). Data were quantified by
densitometry andgraphedasmeanS.E. of three independent experiments; *,p0.05; **,p0.01.C,NRCMswerepre-treatedwith thepharmacological FAK
inhibitor PF-228 (1M) for 1 h prior to the addition of PE (50M) for 24 h. Pre-treatmentwith FAK inhibitor blocked PE-mediated autophagic suppression (right
panel). Data were quantified by densitometry and graphed as mean  S.E. of three independent experiments; *, p  0.05; **, p  0.01. D, NRCMs were
pre-treatedwith FAK inhibitor PF-228 (1M) for 1 h prior to incubationwith PE (50M) for 4 h in the presence of CQ (10M). Autophagic vesicleswere detected
by stainingwith the CYTO-ID autophagy detection kit. ***, p 0.001. Scale bar, 20m. E, quantification of LC3-II levels in basalWT, MFKOmyocyte-restricted
FAK knock-out, and SF2hearts (NS, not significant;n 3–5per group). F–H,MFKO, SF2mice andWT littermates received a single injection of PE (20mg/kg, s.c.).
Hearts were harvested at 24 h, and protein lysates were blotted using indicated antibodies. Blots are representative of 3–5 hearts per group. H, quantification
of LC3-II levels in PE-treated WT, MFKO, and SF2 hearts (**, p 0.01; ***, p 0.001). I and J, SF2 mice were subjected to moderate (I) or severe (J) TAC. Hearts
were isolated at day 3, and protein lysates were blotted with indicated antibodies. Data are representative of three hearts per group.
TABLE 1
Protein sequence of Beclin1 surrounding Tyr-233 in different species
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response. To test this possibility, we first sought to determine
whether Beclin1was required for PE-induced cardiac hypertro-
phy in SF2 mice. To this end, we crossed SF2 mice to available
Beclin1/mice to obtain SF2/Beclin1/ and SF2/Beclin1/
littermates, treated mice with PE for 24 h, and measured heart
weight and cardiomyocyte cross-sectional area. Remarkably,
we found that haplo-insufficiency of Beclin1 significantly atten-
uated the PE-induced cardiomyocyte hypertrophy that is
apparent in SF2 (but not WT) mice at this time point (Fig. 7,
A–C). When coupled with our observation that siRNA-
mediated knockdown of Beclin1 prevented SuperFAK’s ability
to inhibit autophagy in NRCMs (Fig. 5A), these data suggest
that limiting Beclin1-dependent autophagy contributes to the
adaptive increase in myocardial mass induced by PE and FAK.
Accordingly, pre-treatment of NRCMs with the FAK selective
inhibitor, PF-228 not only blocked the PE-mediated autophagy
suppression (refer to Fig. 3, C and D) but also abrogated PE-
induced hypertrophic growth (Fig. 7,D–F). Finally, we explored
a specific role for Tyr(P)-233 Beclin1 in the regulation of myo-
cyte growth. As shown in Fig. 8, ectopic expression of WT
Beclin1 inducedmarked atrophy in starvedHL-1 cells, whereas
ectopic expression of Y233E-Beclin1 did not affect cell size.
Collectively, these studies indicate that FAK-dependent phos-
phorylation of Beclin1 facilitates PE-induced compensatory
hypertrophic growth by suppressing autophagy-dependent
myocyte atrophy.
Discussion
Autophagy promotes the clearance of toxic misfolded pro-
teins and damaged organelles and is necessary to maintain cel-
lular homeostasis, particularly for post-mitotic cells such as
cardiac myocytes that may live for decades. Autophagy is a
highly controlled and precise metabolic function, and dysregu-
lation of autophagy has been implicated in a number of cardio-
FIGURE4.FAK inducesBeclin1phosphorylationonTyr-233.A,COScellswere co-transfectedwithHA-Beclin1andwild-typeFAK, non-phosphorylatable FAK
mutant (Y397F), or SuperFAK. At 24 h, cell lysates were subjected to immunoprecipitation (IP) with anti-HA followed by Western blotting with indicated
antibodies, including an anti-phosphotyrosine antibody (Tyr(P), 4G10).WCL,whole cell lysate. B, protein lysates fromCOS cells co-transfectedwith HA-Beclin1
and non-phosphorylatable FAKmutant (Y397F) or SuperFAK were immunoprecipitated with an anti-HA antibody followed byWestern blotting analysis with
anti-phospho-Beclin1 (Tyr-233).C,COScellswere co-transfectedwith SuperFAKandHA-Beclin1or anon-phosphorylatableBeclin1mutant (Y233F). Cell lysates
were immunoprecipitated with an anti-HA antibody followed byWestern blotting analysis with an anti-phosphotyrosine antibody (Tyr(P), 4G10).D, COS cells
were co-transfectedwith SuperFAKandHA-Beclin1prior to treatmentwith FAK inhibitor PF-228 for 16h. Cell lysateswere immunoprecipitatedwith ananti-HA
antibody followed by Western blotting analysis with anti-phospho-Beclin1 (Tyr-233). E, in vitro Src kinase assay. Purified GST-Beclin1 and GST-Beclin1-Y233F
MAPK were incubated with GST-Src and [-32P]ATP. Samples were analyzed by SDS-PAGE, and the gel was dried and exposed to Kodak XAR film for 2 h,
followed by Coomassie Blue staining. Gel is representative of four separate experiments. F, NRCMs were treated with PE (50 M) for 8 h. Duplicate cell lysates
were blotted with indicated antibodies. G, cardiac-specific SuperFAK transgenic (SF2) mice and littermates received a single injection of PE (20 mg/kg, s.c.).
Hearts were harvested at 24 h, and protein lysates were immunoprecipitated with Beclin1 antibody followed by immunoblotting using indicated antibodies.
Blots represent three hearts per group, and data shown are mean S.E.; p 0.05.
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vascular disorders such as cardiac hypertrophy, myocardial
infarction, and doxorubicin-induced cardiomyopathy (4, 34,
41). Although it is clear that too much or too little autophagy
can be detrimental, themechanisms that underlie the tight spa-
tio-temporal control of autophagy following cardiac stress have
yet to be fully elucidated. Here, we showed that stimulation of
FIGURE5.Phosphorylationof Tyr-233byFAK limitsBeclin1-dependent autophagy.A,Beclin1 is required for SuperFAK-mediated autophagy suppression.
NRCMs were infected with GFP or SuperFAK adenoviruses and transfected with control or Beclin1 siRNAs for 48 h prior to treatment with PE (50 M) for 24 h.
Cell lysateswere blottedwith indicated antibodieswithGAPDHas a loading control. Quantification ofmean S.E. of three independent experiments revealed
that knockdown of Beclin1 reduced SuperFAK-induced increase in p62 protein levels when comparedwith si-Control (right panel). **, p 0.01; ***, p 0.001.
B, FAK activity and FAK-dependent phosphorylation of Beclin1 alters the Beclin1 interactome. HL-1 cells were transfected with HA-Beclin1 or a phosphomi-
metic Beclin1 mutant (Y233E) for 48 h prior to starvation in the presence of FAK inhibitor PF-228 (1 M) or vehicle control for 22 h. Lysates were immunopre-
cipitatedwith anti-HA and subjected toWestern blottingwith indicated antibodies. C, co-immunoprecipitation of endogenous Beclin1with Atg14L in starved
HL-1 cardiomyocytes treated with PF-228 (1 M) or vehicle control for 22 h. D, Beclin Y233E phosphomimetic has limited capacity to induce autophagy. HL-1
cellswere co-transfectedwithGFP-LC3 andHA-Beclin1 or a phosphomimetic Beclin1 variant (Y233E) for 48 hprior to treatmentwith starvation in the presence
of FAK inhibitor PF-228 (1M) and CQ (10M) for 4 h. Cells were fixed and stained for GFP (green), HA (red), and nuclei (DAPI, blue). Beclin1(Y233E)-expressing
cells exhibited less GFP-LC3 puncta (autophagosomes) thanwild-type Beclin1-expressing cells. ***, p 0.001 versuswild-type Beclin1. Results aremean S.E.
of three independent experiments (50 cells were analyzed each group). Scale bar, 10 m. All data were analyzed using two-tailed Student’s t tests.
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1-adrenergic receptor, a major GPCR family member essen-
tial for the development of cardiac hypertrophy, transiently
suppressed autophagy by activation of FAK. Mechanistically,
we demonstrated that direct phosphorylation of Beclin1 at Tyr-
233 by FAK altered Beclin1’s interactome, leading to dimin-
ished autophagic initiation. Moreover, we identified Beclin1 as
a critical mediator of FAK-induced induction of myocyte
hypertrophy, as depletion of Beclin1 blunted the FAK-depen-
dent hypertrophic response to PE.
Despite mounting evidence for a causal role of autophagy
suppression in the promotion of compensatory hypertrophy (4,
11, 31, 42–46), the mechanistic links between pressure over-
load and adrenergic signaling-induced autophagic suppression
have remained largely unsolved. A prior report indicated that
endothelin-1 can suppress autophagy by inducing ubiquitina-
tion and degradation of Atg14L through ZBTB16-Cullin3-
Rock1 E3 ubiquitin ligase complex (47). Interestingly, we found
that PE treatment also impaired Atg14L function, although
through a distinct mechanism. In response to PE stimulation,
FAK-mediated phosphorylation of Beclin1 at Tyr-233 dis-
rupted the Beclin1-Atg14L interaction and suppressed auto-
phagy initiation. Notably, we and others previously reported
that1-adrenergic stimulation of cardiac hypertrophywas aug-
mented by integrin-dependent activation of FAK (21, 22), and
mice deficient in FAK were resistant to pressure overload-in-
duced hypertrophy (23, 24). Although global Beclin1 deple-
tion did not affect basal anabolic heart growth, we showed that
Beclin1 was required for the initial hypertrophic response that
occurs in a PE/FAK-dependent fashion in un-starved mice.
When coupled with our findings that phosphorylation of Tyr-
233 Beclin1 not only suppressed autophagy, but also limited
Beclin1-dependent cardiomyocyte atrophy in vitro, these data
suggest that repression of Beclin1-dependent atrophy is neces-
sary for FAK-dependent compensatory hypertrophic growth.
The blockade of this basal bulk catabolic program likely primes
cardiomyocytes for ensuing hypertrophic growth that occurs
viade novo synthesis of proteins. Interestingly, very recent stud-
ies indicate that autophagy may compete with endocytic recy-
cling as these pathways share common vesicle trafficking
machinery (48, 49). Thus, it is also formally possible that a tem-
porary block of autophagy in the face of continued secretory/
endocytic recycling vesicle trafficking could promote plasma
membrane expansion, an event that could ultimately prevent
growth-induced stress on the plasma membrane and/or de-re-
press a growth-inhibitory negative feedback system. As FAK is
known to be activated byTAC and other hypertrophic agonists,
it will be future interest to determine whether this is a general
mechanism by which these agents lead to suppression of myo-
cyte autophagy-dependent atrophy.
As noted above, Beclin1 has previously been shown to be
phosphorylated by the serine/threonine kinases Mst1 (16),
ROCK1 (18), DAPK and Akt (15) among others (50), and these
post-translational modifications have been shown to either
promote or inhibit Beclin1 autophagy initiation complex for-
mation. Beclin1 protein has a BH3 domain (amino acids 114–
123) that interacts with the autophagy inhibitor Bcl-2/Bcl-xl, a
FIGURE 6. FAK associates with Beclin1 in an activation-specific fashion. A, top, schematic representation of three functional domains of Beclin1 (the
N-terminal Bcl-2 homology 3 domain (BH3), the central coiled-coil domain (CCD), and the C-terminal ECD), and FLAG-tagged (FL) Beclin1 deletion constructs.
Bottom, FAK interaction sites on Beclin1weremapped by co-immunoprecipitation of Beclin1with FAK in COS cells co-transfectedwithMyc-FAK and indicated
FLAG-Beclin1 constructs. B, immunoprecipitation of Beclin1 with FAK in COS cells co-transfected with HA-Beclin1 and wild-type FAK or the non-phosphory-
latable FAKmutant (Y397F). C, immunoprecipitation of Beclin1 with FAK in COS cells co-transfected with HA-Beclin1 and wild-type FAK and incubated FAK
inhibitor 14 (50M for 1 h) prior to lysis.D, immunoprecipitation of Beclin1 with FAK in COS cells co-transfected with FAK(Y397F) and wild-type Beclin1 or the
non-phosphorylatable Beclin1 variant (Y233F). E,model depicting the effect of FAK-mediated Beclin1 phosphorylation on autophagy initiation. Under condi-
tions of nutrient starvation, Beclin1 forms a complex with Atg14L to promote autophagy. In response to neurohormone stimulation or mechanical stretch,
FAK-mediated phosphorylation of Tyr-233 Beclin1 disrupts the Beclin1-Atg14L interaction and suppresses autophagy.
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CCDdomain (amino acids 144–269) that binds autophagy pro-
moting proteins Atg14L, UVRAG, Ambra1, and VPS34 and
mediates Beclin1 homodimer formation, and an ECD domain
(amino acids 244–337) that interacts with VPS34 and the anti-
autophagic protein Rubicon (51). ROCK and DAPK phosphor-
ylate Thr-119 within the BH3 (Bcl-2 binding) domain of
Beclin1, and this phosphorylation limits Bcl-2/Bcl-xl binding
and promotes autophagy (18, 52). In contrast, Mst1 phosphor-
ylation of Beclin1 on a nearby residue (Thr-108) enhances
the binding affinity for Bcl-2/Bcl-xl and limits autophagy (16).
AKT-dependent phosphorylation of Beclin1 also limits
autophagy, but in this case the mechanism involves phos-
pho-Ser-234- and Ser-295-induced formation of a distinct
autophagy-inhibitory Beclin1/14-3-3vimentin intermediate
filament complex (15). Of these serine/threonine Beclin1 phos-
phosites, the MST-1 target Thr-108 is the only one to date that
has been studied in the context of cardiac biology, and these
studies revealed that theAsp-108 phosphomimetic Beclin1 var-
iant reduced cardiomyocyte autophagy and simultaneously
promoted cardiomyocyte apoptosis by promoting the seques-
tration of Bcl-2/Bcl-xl from Bax (16).
Recently, the Levine laboratory (20) reported that Beclin1 is
also a target for tyrosine phosphorylation-dependent regula-
tion. In fact their studies showed that Tyr-233 was one of mul-
tiple tyrosine phosphorylation sites induced by EGFR signaling
that collectively inhibited Beclin1-dependent autophagy.
Mechanistically, EGFR-dependent tyrosine phosphorylation
increasedBeclin1 dimerization, promotedBeclin1 bindingwith
Bcl-2 and Rubicon, and decreased Beclin1VPS34 complex for-
mation (20). However the specific function of Tyr-233 was not
evaluated in their studies. Our studies are the first to show that
Tyr(P)-233 is a major phospho-site in cardiomyocytes in vitro
and in vivo and is the first to describe the consequence of this
phosphosite on Beclin1 activity. We identified Tyr-233 within
the CCD domain of Beclin1 as the sole site of phosphorylation
by FAK. Moreover, we demonstrated that phosphorylation of
Tyr-233 limits association of Beclin1 with the CCD-binding
partner, Atg14L, indicating Tyr-233 is a critical site in defining
the Beclin1 interactome and in modulating Beclin1-mediated
autophagy and cardiomyocyte size. Because Tyr-233 is located
at the antiparallel dimer packing interface of the metastable
(imperfect) Beclin1 homodimer (53), we tested the possibility
that the Y233E mutation might promote homodimer stability
and thus limit themonomeric “pool” available for Atg14L bind-
ing. However, we found that the Y233Emutation did not have a
major effect on Beclin1 dimerization as assessed by co-immu-
noprecipitation nor did it promote inhibitory (Bcl2/Beclin1 or
rubicon/Beclin1) complex formation. This finding is consistent
FIGURE 7. FAK-mediated cardiomyocyte hypertrophy requires Beclin1 and FAK activity. A–C, cardiac-specific SuperFAK transgenic (SF2) or non-trans-
genic (NTG) mice on a Beclin1/ or Beclin1/ background received a single injection of PE (20 mg/kg, s.c.), and hearts were harvested 24 h following
treatment. A, heart weight normalized to tibia length. B and C,myocyte cross-sectional area as assessed by staining with wheat germ agglutinin (red), cardiac
troponin T (green), and DAPI (blue). At least 200 cells from five different fields were analyzed in each heart. *, p 0.05; **, p 0.01. Data are mean S.E. from
3 to 4 animals per group.D–F, pre-treatment with FAK inhibitor abrogated PE-induced cardiomyocyte hypertrophy. NRCMswere treatedwith PE (50M) with
or without FAK inhibitor PF-228 (1M) for 48 h.D, cardiac myocytes were labeled with anti-cardiac troponin T (red), and cell surface area was quantified using
ImageJ software (National Institutes of Health). **, p 0.01. Data are mean S.E. of four independent experiments (200 cells were analyzed each group).
Scale bar, 20m. E, quantitative RT-PCR analysis of hypertrophymarkers ANP (left) and BNP (right). *, p 0.05; **, p 0.01; ***, p 0.001. Data aremean S.E.
of three independent experiments and were analyzed using two-tailed Student’s t tests. ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide.
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with the lack of effect of the phosphomimetic Y233E Beclin1 on
cardiomyocyte apoptosis (data not shown) and our previous
findings that FAK is a cardioprotective kinase (26, 27). Thus,
although we cannot exclude that Tyr-233 phosphorylation
results in subtle changes in dimer stabilization, the studies
above combined with knowledge that only a small fraction of
endogenous Beclin1 exists in a homodimeric form indicate that
phosphorylation of Tyr-233 may alter Atg14L association by a
distinctmechanism (54). In this regard, it is noteworthy that the
nearbyGlu-224 is a critical residue in the electrostatic pairing of
Beclin1 with Atg14L, and thus it will be of interest to determine
whether Tyr(P)-233 interferes with this charge pair (53, 54). In
sum, although the precisemechanismbywhichTyr(P)-233 reg-
ulates Atg14L binding remains to be identified, our study pro-
vides important insight into a novel regulatory pathway that
controls the formation of various Beclin1-VPS34 sub-com-
plexes to modulate autophagic flux. It will be of future interest
to study the differential regulation and consequences of Beclin1
tyrosine and serine/threonine phosphorylations as coordinated
phosphorylation of these sites will likely have amajor impact on
the regulation of Beclin1 function.
Because FAK is activated by EGFR signaling (55), it is likely
that EGFR-induced Beclin1 phosphorylation at Tyr-233 is
mediated, at least in part, by FAK, that phosphorylation of this
site is sufficient to limit complex 1 formation, but that addi-
tional FAK-independent EGFR tyrosine phosphorylations are
necessary to fully attenuate Beclin1-dependent autophagy.
EGFR is known to be transactivated by numerous GPCRs, and
EGFR function is critical for GPCR-stimulated mitogenic
responses; however, further studies are necessary to determine
the extent to which EGFR transactivation regulates PE-medi-
ated autophagy suppression. Nevertheless, given that EGF sig-
naling promotes mitogenic responses in many cell types and
that EGFR-mediated autophagy suppression facilitates tumor
initiation, progression, and acquired resistance to tyrosine
kinase inhibitors (11), the consequence of FAK-dependent
tyrosine phosphorylation of Beclin1 likely reaches beyond the
physiological initiation of cardiac hypertrophy defined herein.
Autophagy is known to be enhanced following cardiac I/R,
but studies targeting various components of this pathway have
led to different conclusions as to whether autophagy is adaptive
or maladaptive in the context of ischemic heart disease (2, 3).
Although treatment with bafilomycin A (which blocks lyso-
somal degradation of autophagosomes) or inhibition of Atg5 (a
protein essential for the capture of ubiquitinated proteins and
LC3-dependent expansion of autophagosomes) worsened I/R
injury and promoted the accumulation of damaged mitochon-
dria in this setting (5, 6), mice haplo-insufficient for Beclin1
that exhibited decreased autophagy were protected from I/R
damage (7, 8). Similar discordant results were observed in pres-
sure overload models of cardiac hypertrophy. Indeed, inactiva-
tion of Atg5 was detrimental, whereas inactivation of Beclin1
was protective (2, 4, 34). Moreover, very recent studies indicate
that the partial suppression of autophagy initiation conferred
by Beclin1 haplo-insufficiency also protected mice from doxo-
rubicin-induced cardiotoxicity (35). The latter studies showed
that doxorubicin blocks autophagic flux by alkalinizing the lys-
osome and that the resultant build-up of autophagosomes con-
tributes to cardiotoxicity. Thus, decreased autophagy initiation
was cardioprotective in this setting as it resulted in a diminished
demand on the lysosomal system. We reason that this mecha-
nism may also contribute to the cardioprotection conferred by
Beclin1 haplo-insufficiency in I/R and TAC models and posit
that FAK-dependent phosphorylation of Beclin1 may act in a
FIGURE 8. Beclin1 but not Y233E Beclin1 induces cardiomyocyte atrophy. HL-1 cells were transfected with HA-Beclin1 WT, HA-Beclin1 Y233E variant, or
empty vector for 48 h. Cells were then fixed in 2%paraformaldehyde and stainedwith HA (red), phalloidin (green), andDAPI (blue). HL-1 cell sizewasmeasured
using ImageJ software. Results aremean S.E. of three independent experiments (50 cells were analyzed each group). Scale bar, 10m.NS, not significant.
Data were analyzed by one-way analysis of variance with Dunnett’s post hoc test.
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similar protective fashion. Indeed, we found that FAK-depen-
dent Beclin1 phosphorylation attenuates complex I formation
and autophagosome formation but permits complex II forma-
tion and the fusion of pre-existing autophagosomes with lyso-
somes thus limiting the build-up of autophagic vesicle interme-
diates. Interestingly, there are striking parallels between
challenged Beclin1/ mice and SF2 mice. Both lines of mice
exhibit preserved systolic function and reduced perivascular
and interstitial fibrosis following I/R or doxorubicin treatment
(7, 26, 27, 35). Moreover, myocardial infarct size and myocyte
apoptosis following I/R was significantly reduced in both mod-
els (8, 26). Thus, it will be of future interest to determine the
extent that FAK-dependent phosphorylation of Beclin1 regu-
lates the pathological progression of ischemic heart disease.
Although themechanismswere previously unclear, integrin-
dependent signals have also long been known to limit auto-
phagy. We now show that FAK suppresses autophagy by phos-
phorylation of Beclin1 at Tyr-233 and that this response is causal
for the initiation of PE/FAK-dependent myocyte hypertrophy.
Tyr-233 lies within the CCD domain of Beclin1, and FAK-depen-
dent phosphorylation of this site limits Beclin1Atg14L complex
formation, reduces bulk autophagy, and limits myocyte atrophy.
This novel mechanism to limit Beclin1 activity has important
implications for future treatmentof avarietyofpathophysiological
processes associated with altered autophagic flux.
Experimental Procedures
Animals—C57BL/6mice were purchased fromCharles River
Laboratories. MFKOmice and cardiac-specific SuperFAK (SF)
transgenic mice (SF2) were generated on a C57BL/6 back-
ground as described previously (23, 26). CAG-RFP-EGFP-LC3
mice were kindly provided by Dr. Thomas G. Gillette (Univer-
sity of Texas Southwestern Medical Center). Beclin1/ mice
were obtained from The Jackson Laboratory. Mice were
injected with phenylephrine (Sigma) at a dose (20 mg/kg, s.c.)
that has previously been shown to induce cardiac hypertrophy
(33) or 0.9% NaCl as a control. In some experiments, cardiac
hypertrophy was induced by pressure overload using the TAC
surgery as described previously (23).
NRCM Isolation and Treatments—NRCMs were isolated
from 2- to 3-day-old Wistar rats using the Neonatal Car-
diomyocyte Isolation System (Worthington) as described pre-
viously (27). Cells were plated on fibronectin-coated dishes and
cultured inMedia 199 supplementedwith 15%FBS, 1%penicillin/
streptomycin, and 100 M BrdU for 24 h and then switched to
serum-freeMedium199with1%penicillin/streptomycin.The fol-
lowing drug concentrations were used: phenylephrine (50 M),
PF-228 (1M), chloroquine (Sigma, 10M) or as indicated.
Adenoviral Infection and siRNA Transfection—Adenoviral
infection was performed at a multiplicity of infection of 50
using adenoviruses for GFP or SuperFAK containing an IRES-
GFP cassette. Transfection with siRNA was carried out using
HiPerfect (Qiagen) following the manufacturer’s protocol. The
following siRNAs were used: rat FAK siRNA (sc-156037, Santa
Cruz Biotechnology), Beclin1 siRNA-1 (CUCAGGAGAG-
GAGCCAUUU(dT)(dT)), Beclin1 siRNA-2 (GGGUAAUAU-
UAAACCACAU(dT)(dT)), and control scrambled siRNA (Life
Technologies, Inc.).
Cell Lines and Plasmid Transfection—HL-1 cells (mouse
atrial cardiomyocyte cell line, a generous gift from Dr. Wil-
liam C. Claycomb) were cultured in Claycomb Medium sup-
plemented with 10% FBS, 1% penicillin/streptomycin, 0.1
mM norepinephrine, and 2 mM L-Glutamine. COS cells
(monkey kidney fibroblast-like cell line) were cultured in
DMEM supplemented with 10% FBS and 1% penicillin/
streptomycin. Plasmid transfection was performed using
Lipofectamine 2000 (Life Technologies, Inc.) for HL-1 cells
or TransIT-LT1 (Mirus Bio) for COS cells as per manufactu-
rer’s instructions.
Immunoprecipitation and Immunoblotting—Protein extracts
were prepared from tissue and cultured cells using RIPA lysis
buffer supplemented with HaltTM protease and phosphatase
inhibitor mixtures (Thermo Scientific), and protein concentra-
tion was measured using the Pierce BCA protein assay kit
(Thermo Scientific). Protein lysates (500g to 1mg)were incu-
bated with mouse anti-HA (sc-7392, Santa Cruz Biotechnol-
ogy) or mouse anti-Myc (catalog no. 2276, Cell Signaling)
bound with Dynabeads Protein G (Life Technologies, Inc.) at
4 °C for 1 h. Precipitated protein complexeswere eluted by boil-
ing in sample buffer for 5 min. For immunoblotting, protein
lysates (10–50 g of protein) were separated by SDS-PAGE,
transferred to PVDF membranes, and blotted with the follow-
ing antibodies: rabbit anti-pFAK (Y397) (44624G, Invitrogen,
1:1000); rabbit anti-pFAK (Y576/577) (catalog no. 3281, Cell
Signaling, 1:1000); rabbit anti-pFAK (Y925) (catalog no. 3284,
Cell Signaling, 1:1000); mouse anti-FAK (clone 4.47, Millipore,
1:1000); mouse anti-phosphotyrosine (4G10, Millipore,
1:1000); rabbit anti-HA (sc-805, Santa Cruz Biotechnolo-
gy, 1:1000); rabbit anti-Beclin1 (sc-11427, Santa Cruz Biotech-
nology, 1:1000); rabbit anti-phospho-Beclin1(Y233) (kind gift
from Dr. Beth Levine, custom-produced by Phosphosolutions
Inc., 1:400); mouse anti-SQSTM1/p62 (ab56416, Abcam,
1:2000); rabbit anti-LC3A/B (catalog no. 12741, Cell Signaling,
1:1000); rabbit anti-VPS34 (catalog no. 4263, Cell Signaling,
1:1000); rabbit anti-Atg14L (PD026, MBL, 1:500); mouse anti-
UVRAG (M160–3, MBL, 1:1000); rabbit anti-FLAG (catalog
no. 2368, Cell Signaling, 1:1000); and rabbit anti-GAPDH (sc-
25778, Santa Cruz Biotechnology, 1:1000).
In Vitro Phosphorylation of Beclin1—Recombinant active
GST-Src (100 ng, Abcam ab60884) was combined with equal
amounts of GST-Beclin1 fusion proteins (1 g each) and
[-32P]ATP (1Ci) in kinase reaction buffer (10mMMOPS, pH
7.2, 5mM glycerol 2-phosphate, 10mMMgCl2, 2mM EGTA, 0.8
mM EDTA, 1 MDTT, and 1 M ATP). After incubation for 15
min at 30 °C, the reaction mixtures were boiled in SDS sample
buffer, resolved by 7.5% SDS-PAGE, and visualized by autora-
diography. Total protein was measured by Coomassie staining.
Autophagic Activity and Flux Assays—HL-1 cells were trans-
fected with GFP-LC3 (kind gift from Dr. Douglas Cyr, Univer-
sity of North Carolina, Chapel Hill) followed by treatment with
FAK inhibitor PF-573228 (Sigma, 1 M) in serum-free media
for 4 h or as indicated. Autophagy was assessed by quantitation
of GFP-LC3 puncta numbers per cell blindly using the ImageJ
software or by immunoblotting for LC3-I/LC3-II and
SQSTM1/p62. In cultured NRCMs, autophagic vacuoles were
stained by using the Cyto-IDTM autophagy detection kit (Enzo
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Life Sciences). To monitor autophagic flux in vitro, cells were
treated with the lysosomal inhibitor chloroquine (10 M) for
4–24 h. For assessment of autophagic flux in vivo, fasted CAG-
RFP-EGFP-LC3 mice received a single injection of PE (20
mg/kg, s.c.) at 0 h, an i.p. injection of the lysosomal inhibitor
bafilomycin A1 (1.5 mg/kg) at 22 h, and mice were euthanized
at 24 h based on a recently published protocol (35). Hearts were
then isolated and processed for frozen sectioning using Tissue-
Tek O.C.T. Compound. During the study period, mice have
free access to water but were deprived of food. Tissue sections
were observed under a Zeiss 700 confocal microscope using the
	63 oil lens. Maturation of autophagosome (neural pH) into
autolysosome (acidic pH) is visualized by the loss of the acid-
sensitive EGFP signal.
Immunofluorescence Staining—NRCMs or HL-1 cells cul-
tured in chamber slides were fixed with 4% paraformaldehyde,
permeabilized with PBS containing 0.1% Triton X-100, and
incubated with mouse anti-cardiac troponin T (MS-295-P,
Thermo Scientific, 1:100), mouse anti-HA (catalog no. 2367,
Cell Signaling, 1:50), and Acti-stain 488 fluorescent phalloidin
(PHDG1, Cytoskeleton, Inc., 100 nM). Paraffin-embedded tis-
sue sections were subjected to deparaffinization, rehydration,
and antigen retrieval as described previously (26). Sectionswere
then incubated with mouse anti-cardiac troponin T (MS-
295-P, Thermo Scientific, 1:100) and wheat germ agglutinin
(W32466, Invitrogen, 1:100). Immunofluorescence signals
were visualized by incubation with appropriated Alexa
Fluor fluorescent-conjugated secondary antibodies (Invit-
rogen) and then observed under a Zeiss LSM 710 confocal
laser-scanning microscope (Zeiss, Germany). Cross-sec-
tional area and surface area of cardiomyocytes were mea-
sured by tracing cell peripheries using ImageJ software
(National Institutes of Health).
Quantitative Reverse Transcription-PCR—Total RNA was
isolated from cells using the Quick-RNATM MiniPrep kit
(Zymo Research), and cDNA was synthesized using the iScript
cDNA synthesis kit (Bio-Rad). Quantitative real time PCR was
performed using the Maxima SYBR Green/ROX quantitative
PCR master mix (Thermo Scientific) in an Applied Biosystems
7500 real time PCR systemwith GAPDH as an internal control.
Primer pairs used were as follows: atrial natriuretic peptide,
5
-CCAGGCCATATTGGAGCAAATCC-3
 and 5
-CATGA-
CCTCATCTTCTACCGGCAT-3
; brain natriuretic peptide,
5
-TGGGAAGTCCTAGCCAGTCTCC-3
 and 5
-CTT-
TTCTCTTATCAGCTCCAGCAGC-3
; and GAPDH, 5
-GCT-
GGCATTGCTCTCAATGACAA-3
 and 5
-GTCCACCAC-
CCTGTTGCTGTA-3
.
Statistics—Results are presented as mean  S.E. Statistical
comparisons between two groups were performed using two-
tailed unpaired Student’s t test. Multigroup comparisons were
performed using one-way analysis of variance followed by post
hoc tests to calculate pairwise differences. A p value of less than
0.05 was considered significant.
Study Approval—All procedures were performed in accord-
ance with National Institutes of Health guidelines for the care
and use of laboratory animals andwere approved by the IACUC
at the University of North Carolina, Chapel Hill.
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